Publicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (9)

2023

  1. Relevance of the organic anion transporting polypeptide 1B3 (OATP1B3) in the personalized pharmacological treatment of hepatocellular carcinoma

    Biochemical Pharmacology, Vol. 214

2022

  1. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

2021

  1. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

    Molecular Metabolism, Vol. 53

  2. Novel pharmacological options in the treatment of cholangiocarcinoma: Mechanisms of resistance

    Cancers, Vol. 13, Núm. 10

2019

  1. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib

    British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800

2018

  1. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1335-1344

2017

  1. Osteopontin regulates the cross-talk between phosphatidylcholine and cholesterol metabolism in mouse liver

    Journal of Lipid Research, Vol. 58, Núm. 9, pp. 1903-1915

2016

  1. Liver Cholesterol Overload Aggravates Obstructive Cholestasis by Inducing Oxidative Stress and Premature Death in Mice

    Oxidative Medicine and Cellular Longevity, Vol. 2016

2002

  1. Evidence for dual effects of DNA-reactive bile acid derivatives (Bamets) on hepatitis B virus life cycle in an in vitro replicative system

    Antiviral Chemistry and Chemotherapy, Vol. 13, Núm. 6, pp. 371-380